Evogene Ltd. Reports Q1 2024 Financial Results
Ticker: EVGN · Form: 6-K · Filed: May 23, 2024 · CIK: 1574565
Sentiment: neutral
Topics: financial-results, 6-K, quarterly-report
TL;DR
Evogene dropped its Q1 2024 earnings report today, check the 6-K for details.
AI Summary
Evogene Ltd. announced its financial results for the first quarter ended March 31, 2024, on May 23, 2024. The company filed a Form 6-K report with the SEC to furnish a press release detailing these results.
Why It Matters
This filing provides investors with an update on Evogene's financial performance and operational status for the first quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine financial results filing and does not introduce new risks.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- March 31, 2024 (date) — End of first quarter
- May 23, 2024 (date) — Date of announcement and filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report Evogene Ltd.'s financial results for the first quarter ended March 31, 2024, by furnishing a press release as an exhibit.
When did Evogene Ltd. announce its first quarter financial results?
Evogene Ltd. announced its financial results for the first quarter ended March 31, 2024, on May 23, 2024.
What period do the financial results in this filing cover?
The financial results cover the first quarter ended March 31, 2024.
Is Evogene Ltd. required to file annual reports on Form 20-F or 40-F?
Yes, Evogene Ltd. indicated it files annual reports under cover of Form 20-F.
Where is Evogene Ltd.'s principal executive office located?
Evogene Ltd.'s principal executive office is located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Filing Stats: 380 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-05-23 07:00:23
Filing Documents
- zk2431498.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 373KB
- exhibit_99-2.htm (EX-99.2) — 44KB
- exhibit_99-2slide1.jpg (GRAPHIC) — 203KB
- exhibit_99-2slide2.jpg (GRAPHIC) — 283KB
- exhibit_99-2slide3.jpg (GRAPHIC) — 111KB
- exhibit_99-2slide4.jpg (GRAPHIC) — 208KB
- exhibit_99-2slide5.jpg (GRAPHIC) — 203KB
- exhibit_99-2slide6.jpg (GRAPHIC) — 112KB
- exhibit_99-2slide7.jpg (GRAPHIC) — 116KB
- exhibit_99-2slide8.jpg (GRAPHIC) — 113KB
- exhibit_99-2slide9.jpg (GRAPHIC) — 152KB
- exhibit_99-2slide10.jpg (GRAPHIC) — 121KB
- exhibit_99-2slide11.jpg (GRAPHIC) — 144KB
- exhibit_99-2slide12.jpg (GRAPHIC) — 160KB
- exhibit_99-2slide13.jpg (GRAPHIC) — 124KB
- exhibit_99-2slide14.jpg (GRAPHIC) — 98KB
- exhibit_99-2slide15.jpg (GRAPHIC) — 154KB
- exhibit_99-2slide16.jpg (GRAPHIC) — 135KB
- exhibit_99-2slide17.jpg (GRAPHIC) — 112KB
- exhibit_99-2slide18.jpg (GRAPHIC) — 224KB
- exhibit_99-2slide19.jpg (GRAPHIC) — 189KB
- exhibit_99-2slide20.jpg (GRAPHIC) — 277KB
- exhibit_99-2slide21.jpg (GRAPHIC) — 151KB
- exhibit_99-2slide22.jpg (GRAPHIC) — 126KB
- exhibit_99-2slide23.jpg (GRAPHIC) — 112KB
- exhibit_99-2slide24.jpg (GRAPHIC) — 85KB
- exhibit_99-2slide25.jpg (GRAPHIC) — 78KB
- exhibit_99-2slide26.jpg (GRAPHIC) — 112KB
- exhibit_99-2slide27.jpg (GRAPHIC) — 124KB
- image0.jpg (GRAPHIC) — 295KB
- 0001178913-24-001817.txt ( ) — 6384KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On May 23, 2024, Evogene Ltd. (" Evogene ") announced its financial results for the first quarter ended March 31, 2024. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") and is incorporated herein by reference. Evogene is holding a conference call on May 23, 2024 to discuss its quarterly results for the quarter ended March 31, 2024 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference. The GAAP financial statements tables contained in the press release attached as Exhibit 99.1 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (" SEC ") File No. 333-277565 ), and Form S-8 (SEC File Nos. 333-193788 , 333-201443 , 333-203856 and 333-259215 ) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 23, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports First Quarter 2024 Financial Results. 99.2 Slide presentation for conference call of Evogene held on May 23, 2024 discussing Evogene's quarterly financial results for the first quarter of 2024.